Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
JSR Life Sciences’ parent company will pay NT$12 billion ($400 million) for Crown Bioscience International, boosting its global footprint and CRO offerings.
Evotec will leverage its iPSC know-how with stem cell-based disease modeling to discover novel drugs for retinal diseases.
The product of a merger of Pluriomics and Axiogenesis, iPSC company Ncardia has signed licensing deals with Roche and Evotec.
X-Chem will screen its DNA-encoded libraries to discover novel antivirals for Gilead.
Enyo Pharma has successfully identified potential targets of its preclinical molecule series EYP002 with Charles River's technology.
HitGen has formed a drug discovery research collaboration with Boehringer Ingelheim to identify novel small-molecule leads.
Bay Area drug discovery company Verge Genomics has formed industry and academic alliances in neuro disorders.
CRO lobby group ACRO wants the government to drill down into what tax reform can mean for research.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.
Bioclinica is looking to broaden its reach with the purchase of MDDX Research & Informatics.